: Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major’ drug maker on development of cancer treatment


The U.S.-listed shares of Nanobiotix S.A. NBTX blasted 221.7% higher on massive volume Friday, to pace all gainers trading on major U.S. exchanges, after the France-based biotechnology company said it entered into final contract negotiations for the commercialization of its cancer treatment. Trading volume exploded to 27.9 million shares, compared with the full-day volume over the past 30 days of about 3,200 shares. The company said the negotiations come after an agreement to a non-binding term sheet with a “major global pharmaceutical company” for development and commercialization of its lead nanotherapeutic candidate…

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Apple hands Warren Buffett’s Berkshire Hathaway a $214 million payout ahead of shareholder weekend
Next articleMichael Brush: Retail sector insiders are betting on no recession: 4 undervalued stocks they like now


Please enter your comment!
Please enter your name here